Healthcare >> CEO Interviews >> September 13, 2002
MIchael MORAN, PhD, has served as Senior Vice President and Chief
Scientific Officer of MDS Proteomics since March 2001. His
responsibilities include the integration of advanced proteomics, drug
discovery and supercomputing efforts toward the discovery and validation
of new drug targets and therapeutic compounds. From September 2000 to
February 2001, Dr. Moran was Vice President Research. From July 1999 to
August 2000, Dr. Moran was the founding Vice President and Chief
Scientific Officer for MDS Ocata, a privately held biotechnology
company, where he was responsible for leading proteomic research efforts
to advance the company in its goal to identify and characterize protein-
protein interactions as a source of novel drug targets. Concurrently, he
was a visiting professor at the Samuel Lunenfeld Research Institute at
Mount Sinai Hospital and a tenured associate professor at the University
of Toronto Faculty of Medicine, lecturing on molecular and medical
genetics. Dr. Moran earned a Bachelor of Science in Biochemistry, and a
PhD from the National Cancer Institute's Laboratory at the University of
Western Ontario. He completed his Fellowship training at Mount Sinai
Hospital between 1986 and 1990. Dr. Moran was a Fellow at the National
Cancer Institute of Canada from 1986 to 1990, an Assistant Professor in
the Banting and Best Department of Medical Research from 1990 to 1995.
Between 1995 and 2000, Dr. Moran was an Associate Professor with tenure
at the Banting and Best Department of Medical Research and Department of
Molecular and Medical Genetics at the University of Toronto. Dr. Moran
has held career Scientist awards from both the National Cancer Institute
and the Canadian Institutes of Health Research. Dr. Moran has presented
and lectured at over 50 international conferences, college and hospital
engagements, and published over 40 articles in peer-reviewed science and
medical journals. He has consulted and collaborated extensively with
various biotech and pharmaceutical companies, and served as member,
chair and scientific officer for various national medical research
granting agency study sections. Profile
ANIL AMLANI, CA has served as Senior Vice-President and Chief Financial
Officer of MDS Proteomics since 2001. From 2000 to 2001, Mr. Amlani was
the Senior Vice President and Chief Financial Officer of Cancom (now
owned by Shaw), responsible for Finance, Treasury, Investor Relations,
Human Resources and Administration. From 1999 to 2000, Mr. Amlani was
the Head of Finance at TD Bank for the Personal and Commercial sector.
He also spent 18 years at AT&T Canada where he held a number of
increasingly senior posts in strategy, finance, business development,
carrier relations, international traffic and business planning. Mr.
Amlani is a Chartered Accountant in Canada as well as in Britain, where
he spent seven years with two prominent companies in London. Mr.
Amlani's extensive corporate expertise also includes mergers and
acquisitions, tax and strategic planning, business analysis and real
estate services. Profile
evolution, and then talk about some of the more important recent events
that have taken place?
Mr. Amlani: The company
